merger, page-19

No worries VVS

If you are also wondering about the technology side as well then the issue with FER revolves around the scalability of a business model that relies heavily on securing and renting quite expensive synchrotron line beam rental.

You see it only intuitively folows that the COGS for the FER test will be enormous in its initial commercial launch phase as a relatively small number of tests needs to be amortised against a very high fixed cost.

For example FER's 2008 US synchrotron cost was $3.3m. If that was a cost only against the 2k trial samples then that equates to $1,650 per sample.

In any case, FER will need permanent line rental slots as patients would be reluctant to wait too long to get their test results. This is not cheap just ask the boys out at Monash.

This is a business model that may struggle until volumes can be high enough to support the high fixed cost component.

This all being said their -ve predicative value trial data certainly looks good.

cheers